Latest NAV & returns of NIPPON INDIA PRIVATE LTD.

Nippon India Pharma Fund - Direct Plan - Growth Plan

Add To Compare

previously known as Reliance Pharma Dir Gr until

NAV on September 22, 2023
Category Equity:
Sector - Healthcare
Investment StyleBox
Large Growth
Total Assets 5,545 cr
Turnover Ratio 18.67%
Expense Ratio 1.01%
Exit Load 1.00%if redeemed within
1 Months
0.00%if redeemed after 1 Months
Returns
  • 1M: -1.61%
  • 1Y: 25.71%
  • 3M: 11.83%
  • 3Y: 15.96%
  • 6M: 28.95%
  • 5Y: 17.29%
Min Investment 5,000
ADDITIONAL INFO
Fund Manager Sailesh Raj Bhan (Since over 18 years) Kinjal Desai (Since over 5 years) Akshay Sharma (Since 10 months)
ISIN INF204K01I50
Fund Family Nippon India
P/E Ratio 36.26
P/B Ratio 5.02
Launch Date January 01, 2013
Benchmark S&P BSE Healthcare TR INR
ASSET ALLOCATION
EQUITY DISTRIBUTION
RISK MEASURES (3 yrs)
vs S&P BSE Healthcare TR INR

Alpha 3.03
Beta 0.96
R-Squared 96.54
Info Ratio 1.03
Tracking Err 2.92
Sortino 1.603
Sharpe 0.900
Std Dev 15.256
Risk -
SECTOR WEIGHTINGS (%)
Financial 0.0%
Industrial 0.0%
Technology 0.0%
Basic Materials 0.0%
Consumer Cyclical 0.0%
Utilities Services 0.0%
Healthcare Services 100.00%
Energy Services 0.00%
Communication Services 0.00%
Consumer Defensive 0.00%
Real Estate 0.00%
INVESTMENT OBJECTIVE

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

You will not receive any dividends. Your investments will get the largest benefit of compounding.

View Factsheet

-
Best Sector Healthcare Funds
NAME LATEST
NAV
RETURNS
1y    
FUND
ASSETS
Expense
RATIO
RISK
25.240 26.39% 3,174 cr 1.21% -


Other plans of Nippon India Pharma


Other Equity funds by Nippon India